Skip to main content

Kidney Transplant Recipients

Nephrology
6
Pipeline Programs
11
Companies
9
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
1
3
Early DiscoveryClinical DevelopmentMarket

Nephrology is a $36.6B mature market dominated by cardiometabolic crossover drugs with limited pure renal innovation.

$36.6B marketMature→ Stable30 products15 companies

Key Trends

  • GLP-1 agonists and SGLT2 inhibitors dominate (69% of spending) due to dual cardio-renal benefits
  • Patent cliffs approaching 2026-2030 create generic conversion risk for blockbuster franchises
  • Pipeline activity remains robust (2,785 trials) but concentrated in early-phase basic research

Career Verdict

Nephrology offers stable employment in commercial and medical affairs roles, but limited growth upside due to mature blockbuster dependency and declining pure renal research focus.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1OZEMPICStable
$9.2B
Novo Nordisk·Peak12.4yr
#2JARDIANCEStable
$8.8B
#4FARXIGAStable
$4.3B
AstraZeneca·Peak15.4yr

Drug Class Breakdown

Glucagon-like Peptide-1 (GLP-1) Agonists
$16.6B(45%)

cardiometabolic dominance

Sodium-Glucose Transporter 2 Inhibitors
$8.8B(24%)

cardioprotective expansion

SGLT2 Inhibitors (dapagliflozin class)
$4.3B(12%)

heart failure crossover

Adrenergic Beta3-Agonists
$3.0B(8%)

overactive bladder niche

Dipeptidyl Peptidase 4 Inhibitors
$1.3B(4%)

declining relevance

Career Outlook

Stable

Nephrology careers are stable but not expanding; the field is supported by blockbuster drugs (GLP-1s, SGLT2i) that face patent cliffs between 2026–2041, creating near-term employment security but long-term uncertainty. Commercial and medical affairs roles dominate hiring, while R&D investment is limited to niche mechanisms (complement inhibition, gene therapy). Career progression depends on specialization in medtech, diagnostics, or orphan nephrology rather than traditional pharma blockbuster development.

Breaking In

Target medtech platforms (Outset, Fresenius) or biotech innovators (Vertex, Calyxo) over traditional pharma; nephrology offers job stability and clinical depth but limited growth trajectory in pure pharmaceutical roles.

For Experienced Professionals

Leverage cardiometabolic expertise to span diabetes, CKD, and HF franchises; position for transition to orphan nephrology (ADPKD, FSGS, IgA) where innovation and valuation multiples are highest.

In-Demand Skills

Renal endpoints and biomarkers (eGFR, albuminuria)Cardio-renal crossover knowledge (diabetes + CKD + HF)Medtech systems expertise (dialysis, transplantation platforms)Medical affairs and key opinion leader management

Best For

Medical Science Liaison (renal specialists)Commercial Manager (established nephro franchise)Clinical Development Manager (rare kidney disease)Real-world evidence analyst (CKD outcomes)

Hiring Landscape

$108K–$330K

Nephrology hiring is concentrated in commercial roles (58 positions, $108K avg) and medical affairs (12 positions, $330K avg), reflecting mature market dynamics. Top hiring companies are innovative platforms (Vertex: 41 jobs) and medtech (Outset: 21 jobs), not traditional pharma. Salary compression in commercial roles suggests commoditization.

124
Open Roles
5
Companies Hiring
4
Departments

Top Hiring Companies

20Growing
8Stable

By Department

Commercial(47%)
$108K
Medical Affairs(10%)
$330K
Clinical Excellence(6%)
$140K
Quality Assurance(4%)
$201K

Hiring favors medtech and biotech platforms over traditional pharma; medical affairs offers premium compensation but limited volume; commercial roles are abundant but underpaid relative to other therapeutic areas.

Competitive Landscape

11 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
2 programs
1
1
mycophenolic acidPhase 41 trial
Enteric-coated Mycophenolate sodiumPhase 31 trial
Active Trials
NCT00239044Completed40
NCT01336296Completed61Est. Apr 2014
Genentech
GenentechCA - Oceanside
1 program
1
Mycophenolate MofetilPhase 41 trial
Active Trials
NCT00199667Unknown137
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
1
PrografPhase 41 trial
Active Trials
NCT01889758Completed78Est. Jan 2016
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
Varivax®Phase 1
MSD
MSDIreland - Ballydine
1 program
1
Varivax®Phase 1
Veloxis Pharmaceuticals
2 programs
Conversion to extended-release tacrolimusPHASE_41 trial
Envarsus XRPHASE_41 trial
Active Trials
NCT06751992Recruiting92Est. Oct 2027
NCT03979365Completed261Est. Mar 2022
Astellas
AstellasChina - Shenyang
1 program
ATF-Fresenius SN/A1 trial
Active Trials
NCT02392312Completed950Est. Mar 2018
Genomics
GenomicsUK - Oxford
1 program
Validation of Gene Expression Markers of Renal Allograft Functional DeclineN/A
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
Validation of Gene Expression Markers of Renal Allograft Functional DeclineN/A1 trial
Active Trials
NCT01782586Completed499Est. Mar 2018
Merck & Co.
Merck & Co.RAHWAY, NJ
1 program
Varivax®PHASE_1
Lee's Pharmaceutical
Lee's PharmaceuticalChina - Guangzhou
1 program
MizoribinePHASE_41 trial
Active Trials
NCT05293704Unknown30Est. May 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Veloxis PharmaceuticalsConversion to extended-release tacrolimus
Lee's PharmaceuticalMizoribine
Veloxis PharmaceuticalsEnvarsus XR
Colorado TherapeuticsPrograf
Sandozmycophenolic acid
GenentechMycophenolate Mofetil
SandozEnteric-coated Mycophenolate sodium
AstellasATF-Fresenius S
Allergy TherapeuticsValidation of Gene Expression Markers of Renal Allograft Functional Decline

Clinical Trials (9)

Total enrollment: 2,148 patients across 9 trials

NCT06751992Veloxis PharmaceuticalsConversion to extended-release tacrolimus

Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients

Start: Mar 2026Est. completion: Oct 202792 patients
Phase 4Recruiting

An Open Study on the Preventive Effect of Early Mizoribine Conversion on BKV Nephropathy in Renal Transplant Recipients

Start: May 2022Est. completion: May 202430 patients
Phase 4Unknown

Envarsus XR Compared to Immediate Release Tacrolimus

Start: Jul 2019Est. completion: Mar 2022261 patients
Phase 4Completed

Pharmacokinetic Studies of Tacrolimus in Transplant Patients

Start: Jun 2013Est. completion: Jan 201678 patients
Phase 4Completed
NCT01336296Sandozmycophenolic acid

Evaluate Effects and Safety of Pre-load Myfortic® in Transplant Patients

Start: Sep 2010Est. completion: Apr 201461 patients
Phase 4Completed
NCT00199667GenentechMycophenolate Mofetil

Concentration Controlled Versus Fixed Dose of MMF in Kidney Transplant Recipients

Start: Oct 2002137 patients
Phase 4Unknown
NCT00239044SandozEnteric-coated Mycophenolate sodium

An Open Label Study to Evaluate the Tolerability and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Combination With Cyclosporine Microemulsion (CsA-ME) in Maintenance Renal Transplant Recipients

Start: Dec 200240 patients
Phase 3Completed
NCT02392312AstellasATF-Fresenius S

Observational Study to Evaluate the Safety and Efficacy of ATG-F on Kidney Transplant Recipients

Start: Jan 2015Est. completion: Mar 2018950 patients
N/ACompleted
NCT01782586Allergy TherapeuticsValidation of Gene Expression Markers of Renal Allograft Functional Decline

Validation of Gene Expression Markers of Renal Allograft Functional Decline

Start: Mar 2013Est. completion: Mar 2018499 patients
N/ACompleted

Related Jobs in Nephrology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 2,148 patients
11 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.